Emmaus Life Sciences, Inc.
EMMA evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $3.6M
- Lead Asset:
- endari (Approved)
What it means
What to watch
Prepared research question
What matters most for EMMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EMMA
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with its only approved product, Endari® (prescription-grade L-glutamine oral powder), for reducing acute complications of sickle cell disease.
Key risk: Single product reliance
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$3.6M
Cash Runway
—
Lead Asset
endari (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for Emmaus Life Sciences, Inc..
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with its only approved product, Endari® (prescription-grade L-glutamine oral powder), for reducing acute complications of sickle cell disease.
- Endari® (prescription-grade L-glutamine oral powder) is FDA-approved to reduce acute complications of sickle cell disease in patients five years of age and older [pipeline].
- As of 2026-06-30, the company reported cash & equivalents of $2.8M, total revenue of $6.3M, net income of $1.3M, shareholders' equity of -$66.2M, and total debt of $28.8M [sec].
- Emmaus has an exclusive license agreement with NeoImmuneTech, Inc. to market, sell, and distribute Endari® in the U.S. and Canada [pipeline].
- The company is exploring L-glutamine oral powder for additional indications, including diverticulosis (preclinical) and pancreatic cancer (option agreement with Cedars-Sinai) [pipeline][news].
- Emmaus also holds an exclusive license from Kainos Medicine, Inc. for an IRAK4 inhibitor (KM10544) targeting leukemia, lymphoma, and solid tumor cancers, currently in preclinical phase [pipeline].
What works
- Endari® is an FDA-approved product for sickle cell disease, providing a commercial revenue stream [pipeline][sec_mda].
- The company has established partnerships for Endari® (NeoImmuneTech) and for pipeline candidates (Telcon RF Pharmaceutical, Kainos Medicine), expanding its commercial and development reach [pipeline].
- Emmaus is actively exploring new indications for its L-glutamine platform, including diverticulosis and pancreatic cancer, which could diversify its product portfolio [pipeline][news].
What to weigh
- Emmaus has negative shareholders' equity of -$66.2M as of 2026-06-30, indicating accumulated losses exceed equity [sec].
- The company's total debt of $28.8M as of 2026-06-30 is high relative to its cash position of $2.8M, suggesting financial leverage [sec].
- Endari® is the only approved product, making the company heavily reliant on a single revenue source [sec_mda].
- Pipeline candidates (PGLG for diverticulosis, KM10544 IRAK4 inhibitor) are in preclinical stages, with no near-term approval expected [pipeline].
From the filings
Quoted directly from source documents.
Endari® is FDA-approved to reduce acute complications of sickle cell disease.
“Our only product, Endari® (prescription-grade L-glutamine oral powder) is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease”
SEC MD&A · November 14, 2025
Emmaus has an exclusive license with NeoImmuneTech for Endari® in the U.S. and Canada.
“Exclusive license to market, sell, and distribute Endari® and any generic equivalents in the U.S. and Canada in exchange for an upfront cash payment”
Risks & what to watch (4)›
Key risks
- Single product reliance — Endari® is the only approved product; pipeline candidates are preclinical, creating revenue concentration risk [sec_mda][pipeline].
- Negative equity and high debt — Shareholders' equity of -$66.2M and total debt of $28.8M as of 2026-06-30 indicate financial strain [sec].
- Limited cash runway — Cash & equivalents of $2.8M as of 2026-06-30 may limit ability to fund operations and R&D without additional financing [sec].
- Preclinical pipeline uncertainty — Pipeline candidates for diverticulosis and IRAK4 inhibitor are preclinical, with no guarantee of clinical success or approval [pipeline].
What to watch
- Progress of the L-glutamine oral powder option agreement with Cedars-Sinai for pancreatic cancer, announced 2026-08-31 [news].
- Any updates on the preclinical PGLG program for diverticulosis and the IRAK4 inhibitor KM10544 [pipeline].
- Financial filings for subsequent quarters to monitor changes in cash position, revenue, and debt levels [sec].
- Potential partnership or licensing developments for Endari® or pipeline candidates [pipeline].
Sources: Catalysts · Competitor trials · News · Pipeline · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run Emmaus Life Sciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Emmaus Life Sciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income $1M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.1%
- Days to cover
- 0.5
- Shares short
- 41,217
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EMMA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Emmaus Life Sciences, Inc.?
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with its only approved product, Endari® (prescription-grade L-glutamine oral powder), for reducing acute complications of sickle cell disease.
What is Emmaus Life Sciences, Inc.'s lead drug candidate?
Emmaus Life Sciences, Inc.'s most advanced tracked candidate is endari (Approved) for reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Who is the CEO of Emmaus Life Sciences, Inc.?
Mr. Willis C. Lee M.S. is the chief executive officer of Emmaus Life Sciences, Inc. (EMMA).
Where is Emmaus Life Sciences, Inc. headquartered?
Emmaus Life Sciences, Inc. (EMMA) is headquartered in Torrance, CA, United States.
What therapeutic areas does Emmaus Life Sciences, Inc. focus on?
Emmaus Life Sciences, Inc. develops therapies across Oncology, Rare Disease, Immunology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.